The stock of TESARO Inc (NASDAQ:TSRO) is a huge mover today! About 858,966 shares traded hands. TESARO Inc (NASDAQ:TSRO) has risen 120.54% since March 2, 2016 and is uptrending. It has outperformed by 112.29% the S&P500.
The move comes after 6 months positive chart setup for the $5.17 billion company. It was reported on Oct, 5 by Barchart.com. We have $153.48 PT which if reached, will make NASDAQ:TSRO worth $2.59 billion more.
Analysts await TESARO Inc (NASDAQ:TSRO) to report earnings on November, 3. They expect $-1.92 EPS, down 15.66% or $0.26 from last year’s $-1.66 per share. After $-1.28 actual EPS reported by TESARO Inc for the previous quarter, Wall Street now forecasts 50.00% negative EPS growth.
TESARO Inc (NASDAQ:TSRO) Ratings Coverage
Out of 12 analysts covering Tesaro Inc (NASDAQ:TSRO), 10 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 83% are positive. Tesaro Inc has been the topic of 15 analyst reports since August 24, 2015 according to StockzIntelligence Inc. Lake Street initiated TESARO Inc (NASDAQ:TSRO) on Friday, February 5 with “Buy” rating. As per Monday, August 24, the company rating was initiated by Leerink Swann. The rating was initiated by Raymond James on Tuesday, September 1 with “Strong-Buy”. The stock of TESARO Inc (NASDAQ:TSRO) has “Buy” rating given on Thursday, March 17 by Citigroup. Bank of America initiated the stock with “Neutral” rating in Tuesday, August 30 report. The firm has “Outperform” rating by Wedbush given on Friday, August 5. The firm has “Outperform” rating by Wedbush given on Thursday, January 21. The stock of TESARO Inc (NASDAQ:TSRO) has “Outperform” rating given on Friday, May 13 by Credit Suisse. As per Tuesday, July 19, the company rating was initiated by Robert W. Baird. The stock of TESARO Inc (NASDAQ:TSRO) earned “Buy” rating by Mizuho on Friday, August 5.
According to Zacks Investment Research, “Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company’s product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 1.55 in 2016 Q2. Its up 0.32, from 1.23 in 2016Q1. The ratio is positive, as 24 funds sold all TESARO Inc shares owned while 36 reduced positions. 34 funds bought stakes while 59 increased positions. They now own 44.90 million shares or 3.32% less from 46.44 million shares in 2016Q1.
Gam Ag accumulated 7,000 shares or 0.01% of the stock. Blackrock Advisors Lc last reported 227,610 shares in the company. Nicholas Prtnrs Ltd Partnership holds 0.08% of its portfolio in TESARO Inc (NASDAQ:TSRO) for 13,365 shares. Moreover, Federated Investors Inc Pa has 0.09% invested in TESARO Inc (NASDAQ:TSRO) for 381,400 shares. Pacad has 0.03% invested in the company for 2,800 shares. Dafna Cap Management Ltd Liability holds 30,000 shares or 2% of its portfolio. Bluestein R H And holds 3,000 shares or 0.02% of its portfolio. The Germany-based Deutsche Bancorp Ag has invested 0.02% in TESARO Inc (NASDAQ:TSRO). Pictet Asset Limited has 0.08% invested in the company for 418,730 shares. Venbio Select Advisor Ltd Liability Co last reported 514,000 shares in the company. Tudor Invest Corporation Et Al reported 4,851 shares or 0.01% of all its holdings. Manufacturers Life Insur Com The reported 17,358 shares or 0% of all its holdings. Moreover, Eam Investors Ltd Limited Liability Company has 0.43% invested in TESARO Inc (NASDAQ:TSRO) for 33,741 shares. Bamco Incorporated Ny, a New York-based fund reported 3,700 shares. Pioneer Mgmt holds 118,003 shares or 0.04% of its portfolio.
Insider Transactions: Since June 10, 2016, the stock had 0 insider buys, and 5 selling transactions for $4.39 million net activity. Hanke Jeffrey H. also sold $2.51 million worth of TESARO Inc (NASDAQ:TSRO) shares. The insider English Edward C sold 7,000 shares worth $619,803. Huber Martin H. Jr. had sold 408 shares worth $44,113.
TSRO Company Profile
TESARO, Inc. (TESARO), incorporated on March 26, 2010, is an oncology-focused biopharmaceutical company. The Firm acquires, in-licenses and develops oncology product candidates. The Firm operates in business of developing and commercializing oncology-focused therapeutics segment. The Firm has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.